Global Chemotherapy Induced Acral Erythema Market Growth Analysis 2022Posted by sandeep gade on October 26th, 2022 Increase in usage of chemotherapeutic agents due to increasing prevalence of cancers is the major growth driver of chemotherapy induced acral erythema treatment market. Acral erythema is also known as hand-foot syndrome or palmoplantar erythrodysesthesia. Acryl erythema is a result of adverse drug reaction typically occur after several months of treatment with chemotherapeutic agents. Being the major cause of death, it is estimated 18.1 million new cases of cancer and 9.5 million cancer related deaths worldwide. By 2040, the annual number of cancer cases is expected to increase to 29.5 million and the number of cancer deaths is expected to increase to 16.4 million. The increased prevalence of cancer is to explode new cases of acral erythema and promote the chemotherapy-induced acral erythema market. Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32633 This also creates a window for acral erythema and industrial demand window for acral erythema. Another important factor in the acral erythema market is the increased elderly population. People get older and more susceptible to cancer because of their current lifestyle. All of these factors also affect the acral erythema market as they increase the number of patients receiving chemotherapy each year. Increasing prevalence of cancer propel the growth of chemotherapy-induced acral erythema market. ActiPatch® (BioElectronics Corporation, 2016), is a non-invasive, electroceutical device which uses electromagnetic fields to modulate efferent nerve activity which reduces the pain. Innovate Pharmaceuticals developed an innovative novel liquid formulation of aspirin. Innovate Pharmaceuticals has received crucial support from GC Business Growth Hub and MATMED for human clinical trials to test how the drug helps patients with both Covid-19 and cancer. GSK Consumer Healthcare launched, New Advil Dual Action with Acetaminophen Over-The-Counter Oral Pain Relief Category in 25 Years in the U.S. Teva Announces Launch of First Generic Celebrex® Capsules in the U.S. in 2014. Additionally, increased investment in research and development and technological advancement in the acral erythema treatment is expected to underpin the growth of the chemotherapy-induced acral erythema market. Request for Table of Content@ https://www.persistencemarketresearch.com/toc/32633 300 000 new cases of cancer diagnosed each year among children aged 0-19 years. Increasing cases of cancer can led to increase in cases of acral erythrma. This will primarily boost the expected market growth in the region. ACADIA Pharmaceuticals acquired CerSci Therapeutics in 2020, a developer of treatments for pain and other neurological conditions, for .5M. With the acquisition of IFM Tre, Novartis adds clinical and preclinical anti-inflammatory programs to its portfolio. Swiss company pays 0 million upfront to access IFM Tre’s portfolio of NLPR3 antagonists, comprising one clinical program and two preclinical programs.
Sanofi has entered into an agreement to sell its anti-inflammatory portfolio to the Italian company Fidia Farmaceutici to streamline its products, established in March 2021. Access Full Report@ https://www.persistencemarketresearch.com/checkout/32633 Key Segments By Product Type
By Distribution Channel
About Us: Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein. Contact Us: Persistence Market Research Like it? Share it!More by this author |